Your session is about to expire
← Back to Search
COVID-19 Prevention Education for Diverse Criminal Legal Involved Communities
N/A
Recruiting
Led By John Schneider, MD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
Study Summary
This trial will look at how to engage people with law enforcement ties in COVID-19 prevention education & network mobilization to increase testing & vaccination. 800 participants will be enrolled in two arms.
Who is the study for?
This trial is for adults over 18 who spend most of their time in the recruitment area, speak English, and have had interactions with law enforcement. It's not for those unable to consent or currently showing COVID-19 symptoms as per CDC guidelines.Check my eligibility
What is being tested?
The study tests two methods to promote COVID-19 prevention among people involved with the legal system: one group receives educational sessions on prevention, while the other participates in a network-driven motivational program.See study design
What are the potential side effects?
Since this trial focuses on education and motivation rather than medical treatments, traditional side effects are not applicable. However, participants may experience stress or discomfort discussing health-related topics.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
COVID-19 Testing
COVID-19 Vaccination
Trial Design
2Treatment groups
Active Control
Group I: Education ArmActive Control1 Intervention
The Education condition will include COVID-19 prevention messaging and an interactive activity reinforcing the messages. Testimonial videos will be played including those that describe the testing experience and motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors.
Group II: Motivational ArmActive Control1 Intervention
Study participants randomized to the Motivational Intervention will receive the intervention using a social network diffusion approach. This is a Type I network intervention that includes specific training on mobilization of network members. The Motivational intervention will be based upon a previous workshop divided into four learning and practice modules.
Find a Location
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,013 Previous Clinical Trials
733,310 Total Patients Enrolled
12 Trials studying COVID-19
35,708 Patients Enrolled for COVID-19
John Schneider, MDPrincipal InvestigatorUniversity of Chicago
2 Previous Clinical Trials
1,508 Total Patients Enrolled
1 Trials studying COVID-19
1,328 Patients Enrolled for COVID-19
Russell Brewer, DrPHPrincipal InvestigatorUniversity of Chicago
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am currently experiencing symptoms of COVID-19.I am 18 years old or older.You have had contact with law enforcement in the past.
Research Study Groups:
This trial has the following groups:- Group 1: Education Arm
- Group 2: Motivational Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger